Onconova Therapeutics Inc. (ONTX) |
|
0.28 0.004 (1.49%)
|
10-01 09:07 |
|
Open: |
0.2721 |
Pre. Close: |
0.2759 |
|
High:
|
0.28 |
Low:
|
0.265 |
|
Volume:
|
5,292,281 |
Market Cap:
|
51M |
|
|
|
|
Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. The company is headquartered in Newtown, Pennsylvania and currently employs 25 full-time employees. The firm operates through the identification and development of oncology therapeutics segment. The company is focused on discovering and developing small molecule drug candidates to treat cancer. The firm has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells. The company has over three clinical-stage product candidates and various preclinical programs that target kinases, cellular metabolism or cell division in preclinical development. The firm's lead product candidate, rigosertib, is being tested in both intravenous (IV) and oral formulations as a single agent, and the oral formulation is also being tested in combination with azacitidine, in clinical trials for patients with myelodysplastic syndromes (MDS), and related cancers. Its other product candidates include Briciclib and Recilisib. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.28 - 0.283 |
0.283 - 0.284 |
|
Low:
|
0.265 - 0.268 |
0.268 - 0.269 |
|
Close:
|
0.277 - 0.281 |
0.281 - 0.283 |
|
Technical analysis |
as of: 2020-09-30 4:44:56 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 0.40 One year: 0.51 |
| Support: |
Support1: 0.19 Support2: 0.16 |
| Resistance: |
Resistance1: 0.34 Resistance2: 0.44 |
| Pivot: |
0.27 |
| Moving Average: |
MA(5): 0.28  MA(20): 0.26
MA(100): 0.60 MA(250): 0.50 |
| MACD: |
MACD(12,26): -0.08 Signal(9): -0.11 |
| Stochastic oscillator: |
%K(14,3): 34.36 %D(3): 37.38 |
| RSI: |
RSI(14): 38.00 |
| 52-week: |
High: 1.56 Low: 0.10 Change(%): -65.6 |
| Average Vol(K): |
3-Month: 2345122 10-Days: 3495118 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed above its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.ONTX has closed below upper band by 45.1%. Bollinger Bands are 62.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to ONTX's normal range. The bands have been in this narrow range for 11 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Headline News |
Tue, 29 Sep 2020
The Forecast Just Changed on Onconova Therapeutics Inc. (NASDAQ:ONTX) - The Oracle Dispatch
Mon, 28 Sep 2020
Roll up the Sleeves! When the bell rang at previous close Onconova Therapeutics Inc. (ONTX) was down -3.69% - The InvestChronicle
Mon, 21 Sep 2020
Onconova Therapeutics Announces Initiation of a Phase 1 Clinical Trial of ON 123300 in China by Partner HanX Biopharmaceuticals - GlobeNewswire
Fri, 18 Sep 2020
Onconova Therapeutics Inc (ONTX) Stock: What Does the Chart Say? - InvestorsObserver
Fri, 18 Sep 2020
Onconova Therapeutics, Inc. (ONTX) Stock Behavior Isn’t As Predictable As You Think - Stocks Register
Thu, 17 Sep 2020
Onconova Therapeutics Inc. (ONTX) Open at price of $0.232: A Brand-New Opportunity for Investors - News Daemon
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
 |
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
 |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Underperform |
Price to Earnings: |
Underperform |
| Return on Equity: |
Underperform |
Debt to Equity: |
Outperform |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
184 |
| Shares Float (M) |
179 |
|
% Held by Insiders
|
0.91 |
|
% Held by Institutions
|
11.16 |
|
Shares Short (K)
|
10,560 |
|
Shares Short P. Month (K)
|
11,490 |
Stock Financials |
|
EPS
|
-0.243 |
|
EPS Est This Year
|
-2.860 |
|
EPS Est Next Year
|
-2.100 |
|
Book Value (p.s.)
|
0.090 |
|
Profit Margin
|
|
|
Operating Margin
|
-11587.07 |
|
Return on Assets (ttm)
|
-79.2 |
|
Return on Equity (ttm)
|
-411.8 |
|
Qtrly Rev. Growth
|
-97.2 |
|
Gross Profit (p.s.)
|
0.012 |
|
Sales Per Share
|
0.001 |
|
EBITDA (p.s.)
|
-0.127 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-21 |
|
Levered Free Cash Flow (M)
|
-12 |
Stock Valuations |
|
PE Ratio
|
-1.15 |
|
PEG Ratio
|
|
|
Price to Book value
|
3.09 |
|
Price to Sales
|
254.27 |
|
Price to Cash Flow
|
-2.42 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
